abdominal pain jaundice

This item was filled under [ Most Popular ]

New England Journal of Publishes PROVE 3 Trial Showing Telaprevir-Based Regimens Significantly Increased …
CAMBRIDGE, Mass.—-In a clinical trial known as PROVE 3 published in this week’s New England Journal of Medicine, treatment with telaprevir-based regimens significantly increased rates of sustained viral response in patients with genotype 1 hepatitis C virus infection who did not achieve SVR with at least one prior course of pegylated-interferon and ribavirin therapy.
Reese discovers Hepatitis at a young age


Related Blogs

Be Sociable, Share!


Top Searches Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.



#